Accellent Inc. Announces Timing of Second Quarter 2012 Earnings Release and Conference Call

Accellent Inc. Announces Timing of Second Quarter 2012 Earnings Release and Conference Call

Investor Contact

[email protected]

Accellent Inc., a wholly owned subsidiary of Accellent Holdings Corp., announced today that it will release second quarter 2012 results on Thursday August 9, 2012 and will hold its quarterly conference call to discuss those results at 5:00 P.M. (Eastern Time) that day.

The teleconference can be accessed live on the internet through the Investor Relations section of the Accellent web site at or by calling (800) 901-5231pass code 96577553. Participants should dial in or visit our website 10 to 15 minutes prior to the beginning of the call to download and install any necessary audio software.

A replay of the conference call will be available via or by telephone at (888) 286-8010 pass code 68182013 beginning August 9, 2012 at 7:00 p.m. through August 16, 2012 at 11:59 P.M. In addition, the earnings release and other pertinent financial information will be available in the Investor Relations section of the Company’s website at the time of the conference call.

Accellent Holdings Corp., through its wholly owned subsidiary Accellent, Inc., provides fully integrated outsourced manufacturing and engineering services to the medical device industry primarily in the cardiology, endoscopy and orthopaedic markets. Accellent has broad capabilities in precision component fabrication, finished device assembly, complete supply chain management capabilities and engineering services. These capabilities enhance customers’ speed to market and return on investment by enabling them to refocus internal resources more efficiently. For more information, please visit .

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.